CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

Trial Profile

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs CART 30 (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2016 Results from Phase I part of this trial (n=18) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 22 May 2015 According to a Cellular Biomedicine media release, data from this study were presented at the 10th Annual World Stem Cells & Regenerative Medicine Congress 2015.
    • 22 May 2015 Results published in a Cellular Biomedicine media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top